IDEAYA Biosciences, Inc.

NASDAQ:IDYA

Biotechnology

Healthcare
$26.49 -1.45%

-$0.45 today

Market cap
$2.56B
Beta
-0.05
P/E (TTM)
-19.5
EPS (TTM)
-$1.58
52W Low $20.50High $39.28

Volume 1.45M

Average 1.44M

IDYA Interest Expense

Cost of servicing the company's debt during the period.

IDEAYA Biosciences, Inc.NASDAQ: IDYA

Interest Expense · Q1 FY2026 · quarter ended Mar 2026

Interest expense remains negative

Q1 FY2026 interest expense was $0, compared with $0 a year earlier. Trailing-twelve-month interest expense was $0.

Context

  • Interest expense amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Interest expense increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly interest expense holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMMar 2026
$0— YoY
Interest Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Interest Expense history

USD · from the income statement

Latest · FY2025
0 USD
Year-over-year change
—

Interest Expense vs competitors

How IDYA compares with its peers on the latest reported figures

  • IDYA's LTM Mar 2026 interest expense of $0 is the 4th highest of the 9 companies compared; the peer median is $0.
  • Interest expense amounts to 0.0% of revenue for IDYA, versus a peer median of 0.0%.
IDYA Competitors Peer median
Interest Expense for IDYA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RVMDRevolution Medicines, Inc.LTM Jun 2026$59.34M ———
COGTCogent Biosciences, Inc.LTM Jun 2026$5.18M +1549.0%-8.4%—
VSTMVerastem, Inc.LTM Mar 2026$1.33M -63.4%-18.9%2.7%
IDYAIDEAYA Biosciences, Inc.LTM Mar 2026$0 ——0.0%
ERASErasca, Inc.LTM Sep 2026$0 ———
TNGXTango Therapeutics, Inc.LTM Sep 2026$0 ———
NRIXNurix Therapeutics, Inc.LTM Aug 2026$0 ——0.0%
PRLDPrelude Therapeutics IncorporatedLTM Mar 2026$0 ——0.0%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$0 ——0.0%
Peer median (excluding IDYA) $0+742.8%-13.7%0.0%

Competitors are the stored peer set for IDYA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue27.94M50.93M23.39M7M218.71M
Cost of Revenue1.73M2.1M4.01M3.83M4.59M
Gross Profit26.22M48.83M19.38M3.17M214.12M
Gross Margin93.8%95.9%82.9%45.2%97.9%
Research & Development58.16M89.54M129.51M294.67M314.7M
Selling, General & Admin18.33M21.8M24.3M35.47M63.32M
Operating Expenses76.48M111.33M153.81M330.14M373.43M
Depreciation & Amortization1.73M2.1M4.01M3.83M4.59M
EBITDA(48.04M)(56.55M)(108.95M)(270.64M)(109.11M)
EBITDA Margin-171.9%-111.0%-465.9%-3866.3%-49.9%
Operating Income(50.27M)(62.5M)(134.43M)(326.98M)(159.31M)
Operating Margin-179.9%-122.7%-574.9%-4671.1%-72.8%
Interest Income506K3.85M21.47M52.5M45.62M
Interest Expense00000
Other Income / Expenses506K3.85M21.47M52.5M45.62M
Income Before Tax(49.76M)(58.66M)(112.96M)(274.48M)(113.7M)
Pre-Tax Margin-178.1%-115.2%-483.0%-3921.1%-52.0%
Income Tax Expense00000
Net Income(49.76M)(58.66M)(112.96M)(274.48M)(113.7M)
Net Margin-178.1%-115.2%-483.0%-3921.1%-52.0%
EPS (Basic)(1.41)(1.42)(1.96)(3.36)(1.28)
EPS (Diluted)(1.41)(1.42)(1.96)(3.36)(1.28)
Weighted Avg Shares35.25M41.44M57.52M81.68M88.49M
Weighted Avg Shares (Diluted)35.25M41.44M57.52M81.68M88.49M

IDEAYA Biosciences, Inc.

NASDAQ:IDYA

Intrinsic Alpha fair value

Locked

Current Price

$26.49

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.